Fig 1: The risk model exhibits high prognostic value in the TARGET discovery cohort. (A) OS tissues in TARGET were divided into low- and high-risk groups, according to median risk scores. (B) Kaplan survival analysis indicated the difference between low- and high-risk group OS tissues in TARGET. (C–E) ROC analyses of the risk model for the 1-year, 3-year, and 5-year survival rates for OS patients in TARGET. (F) Alive and death cases between low- and high-risk group OS tissues in TARGET. (G) Expression of COL22A1, CDK6, RNASE6 and AOC3 between low- and high-risk group OS tissues in TARGET.
Fig 2: Three distinct fibroblastic populations are found in articular ligaments.a Left, sub-clustering of fibroblasts (cells from clusters 0, 2, and 4 are shown in Fig. 1a). Right, fraction of each sub-cluster in the ACL and MCL. b Marker genes for each subcluster are illustrated. Dot size represents the percentage of cells expressing a gene within a cluster. The intensity of the dot color indicates the mean expression level. c Violin plots of sub-clusters expressing specific collagens (Col14a1, Col12a1, and Col22a1). d, e Violin plots of tendon stem progenitor cells (TSPC) (d) and chondrogenic markers (e) in the ACL and MCL. f–h Immunostaining of Col22a1 (f), Col14a1 (g) and Col12a1 (h) in the MCL and ACL. Left, low magnification of the region of interest (ROI) indicated by the magenta square. Right, higher magnification of the ROI. Scale bar: 100 µm. i–k Gene ontology analysis shows pathways upregulated in subcluster 0 (Col14a1-positive) (i), sub-cluster 1 (Col12a1-positive) (j) and sub-cluster 2 (Col22a1-positive) (k).
Fig 3: The risk model exhibits high prognostic value in the GSE21257 verification cohort. (A) OS tissues in GSE21257 were divided into low- and high-risk groups according to median risk scores. (B) Kaplan survival analysis indicated the difference between low- and high-risk group OS tissues in GSE21257. (C–E) ROC analysis of the risk model for the 1-year, 3-year, and 5-year survival rates for OS patients in GSE21257. (F) Alive and death cases between low- and high-risk group OS tissues in GSE21257. (G) Expression of COL22A1, CDK6, RNASE6 and AOC3 between low- and high-risk group OS tissues in GSE21257.
Fig 4: The risk model has the potential to predict metastasis in patients with OS. (A) Non-metastasis and metastasis cases between low- and high-risk group OS tissues in the TARGET and GSE21257 cohorts. (B) ROC analysis for the diagnostic value of the risk model in the prediction of OS tissue metastasis. (C, D) IHC was performed to detect the expression of COL22A1, CDK6, RNASE6 and AOC3 in non-metastasis and metastasis OS tissues (magnification 200× and 400×). *p < 0.05; **p < 0.01; ns, no significant.
Fig 5: Construction of a risk model. (A) Univariate COX regression analysis for the 94 genes associated with the infiltration of resting dendritic cells. (B, C) LASSO analysis for other important genes associated with the survival rate of OS. (D) The HR and p value of genes (including AOC3, CDK6, COL22A1 and RNASE6) under multivariate COX analysis are shown.
Supplier Page from Abcam for Anti-COL22A1 antibody